Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Mattingly, Greg W ^a   Weisler, Richard H ^b,c   Young, Joel ^d   Adeyi, Ben ^e   Dirks, Bryan ^e   Babcock, Thomas ^e   Lasser, Robert ^e   Scheckner, Brian ^e   Goodman, David W ^f  

^a St Charles Psychiatric Associates/Midwest Research   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Rochester Center for Behavioral Medicine   (United States)

^e SHIRE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adults; Attention deficit hyperactivity disorder (ADHD); Lisdexamfetamine dimesylate (LDX); Remission; Response

Indexed keywords

LISDEXAMFETAMINE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FOLLOW UP; HUMAN; INSOMNIA; IRRITABILITY; MULTICENTER STUDY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84873511167     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-39     Document Type: Article

References (29)

1. Scahill L, Schwab-Stone M. Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am 2000, 9(3):541-555. vii.
2. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163(4):716-723. 10.1176/appi.ajp.163.4.716, 2859678, 16585449.
3. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006, 59(9):829-835. 10.1016/j.biopsych.2005.09.011, 16373066.
4. Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007, 68(2):268-277. 10.4088/JCP.v68n0213, 17335326.
5. Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, Biederman J, on behalf of the 303 study group Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008, 69(9):1364-1373. 10.4088/JCP.v69n0903, 19012818, on behalf of the 303 study group.
6. Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK, Read SC, Tulloch SJ, on behalf of the SLI381.303 Study group Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006, 11(8):625-639. on behalf of the SLI381.303 Study group.
7. Culpepper L, Mattingly G. A practical guide to recognition and diagnosis of ADHD in adults in the primary care setting. Postgrad Med 2008, 120(3):16-26. 10.3810/pgm.2008.09.1904, 18931467.
8. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010, 71(6):754-763. 10.4088/JCP.08m04902pur, 20051220.
9. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation 1998, New York, NY: Guilford Press.
10. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991, 48(9):851-855. 10.1001/archpsyc.1991.01810330075011, 1929776.
11. Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, et al. The international society for bipolar disorders (ISBD) task force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009, 11(5):453-473. 10.1111/j.1399-5618.2009.00726.x, 19624385.
12. Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field?. Clin Ther 2006, 28(11):1892-1908. 10.1016/j.clinthera.2006.11.006, 17213010.
13. Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology 1976, 218-222. Rockville, MD: US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch.
14. Goodman D, Faraone SV, Adler LA, Dirks B, Hamdani M, Weisler R. Interpreting ADHD rating scale scores: linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Primary Psychiatry 2010, 17(3):44-52.
15. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000, 157(5):816-818. 10.1176/appi.ajp.157.5.816, 10784477.
16. Keck PE, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, Bourne ML, Haggard P. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998, 155(5):646-652.
17. American Psychiatric Association Attention-deficit and disruptive behavior disorders. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 2000, 85-93. Washington, DC: American Psychiatric Association, American Psychiatric Association.
18. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001, 40(2):168-179. 10.1097/00004583-200102000-00011, 11211365.
19. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003, 112(5):e404. 10.1542/peds.112.5.e404, 14595084.
20. Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L, on behalf of the 304 study group Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 2009, 14(10):573-585. on behalf of the 304 study group.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn 1958, 53:457-481.
22. Young J, Mattingly G, Weisler R, Squires L, Adeyi B, Dirks B, Babcock T, Scheckner B. Response and symptomatic remission in a long-term trial of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Poster Present Am Psychiatr Assoc 162nd Annu Meeting 2009, San Francisco, CA.
23. Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009, 259(2):120-129. 10.1007/s00406-008-0845-4, 19165529.
24. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Trott GE, Lee E, Buitelaar JK. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008, 63(10):981-989. 10.1016/j.biopsych.2007.11.008, 18206857.
25. Adler LA, Spencer T, McGough JJ, Jiang H, Muniz R. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord 2009, 12(5):449-459. 10.1177/1087054708320397, 19218542.
26. Epstein JN, Langberg JM, Lichtenstein PK, Altaye M, Brinkman WB, House K, Stark LJ. Attention-deficit/hyperactivity disorder outcomes for children treated in community-based pediatric settings. Arch Pediatr Adolesc Med 2010, 164(2):160-165. 10.1001/archpediatrics.2009.263, 20124145.
27. Sciberras E, Roos LE, Efron D. Review of prospective longitudinal studies of children with ADHD: mental health, educational, and social outcomes. Curr Atten Disord Report 2009, 1:1171-1177.
28. Buitelaar J, Wilens T, Zhang S, Ning Y, Feldman P. What level of ADHD symptom reduction is necessary for functional improvement?. Abstract presented at: American Psychiatric Association 161st Annual Meeting; May 3-8 2008, Washington, DC: American Psychiatric Association, Abstract NR6-016.
29. American Psychiatric Association DSM-5: The Future of Psychiatric Diagnosis 2012, http://www.dsm5.org/Pages/Default.aspx. Accessed February 29, 2012, American Psychiatric Association.